| Today's Big NewsSep 30, 2022 |
| By Max Bayer Nearly six months after slashing more than a third of its workforce, Solid Biosciences is hoping to get on firmer footing through addition, not subtraction. The company is acquiring fellow gene therapy developer AavantiBio and raking in $75 million in new financing. |
|
|
|
By Nick Paul Taylor Zealand Pharma’s phase 3 short bowel syndrome study has hit its primary endpoint, delivering data that could equip it to seek approval for a challenger to Takeda’s Gattex. |
Sponsored By THREAD One aspect of study design to consider when building better research experiences for patients is a genuinely patient-centered eCOA (electronic clinical outcome assessment) program. Here are some tips for ensuring that your eCOA is built with the needs of patients in mind and able to deliver the kind of engagement necessary for successful trials. |
Sponsored By Agilex Biolabs Australia’s largest and most technologically advanced provider of regulated bioanalysis and toxicology studies increases capacity by 500% with addition of new in-vivo facility in Brisbane |
By Nick Paul Taylor Kinarus Therapeutics is the latest company to swing and miss at the hospitalized COVID-19 opportunity. After seeing a who’s who of biopharma companies fail, the Swiss biotech has pulled the plug on a phase 2 clinical trial in response to the lackluster efficacy data reviewed at an interim analysis. |
By James Waldron Having overcome FDA trial issues last year, Rocket Pharmaceuticals expects the latest early-stage data for its heart disease drug to give the gene therapy a long-awaited boost into phase 2 trials. |
By Gabrielle Masson As the cell and gene field builds off a quarter of great scientific progress, the industry may be teetering on the brink of transforming medicine as we know it. |
By Zoey Becker After a long and winding road filled with AdComms, the FDA has finally approved Amylyx's ALS drug, Relyvrio. In an interview with Fierce Pharma, the company's co-founders say there is more research to be done and more drugs to be made to meet the unmet needs of ALS patients. |
By Max Bayer Merck's Keytruda has dazzled since first nabbing approval in 2014, earning billions of dollars in revenue and expanding its reach to more than a dozen cancers. But as the drug's patent expiration nears, can Merck manufacture a second clinical lightning strike? |
By Helen Floersh Pinning down backup genes along with the metabolic pathways they’re regulating, has historically required tedious screenings that gave limited information about how different genes interact. Now, a team of researchers has used machine learning to streamline the process and add context that could make precision medicines more precise. |
By Conor Hale The agency’s latest approval for Acuvue Abiliti adds to its number of potential users by allowing the lenses to be offered with stronger vision correction prescriptions. |
By Teresa Carey This week on "The Top Line," we talk with many of the Fierce 15 honorees to find out what makes them unique. We also share highlights from the Fierce Biotech Summit on gene editing innovations and battling biotech's bear market. |
By Gabrielle Masson,Max Bayer Moderna promotes Andres to new future-looking strategy role. Troubled CytoDyn unveils new president amid pipeline pivot. GSK set to bring on Burberry CFO for same role after Mackay retires. |
By Angus Liu Eisai and Biogen's lecanemab clinched a surprise phase 3 Alzheimer's win. Astellas got a less-than-ideal temporary injunction against a Pfizer generic to Lexiscan. Novartis sold a Sandoz Chinese plant to a local CDMO. And more. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we talk with many of the Fierce 15 honorees to find out what makes them unique. We also share highlights from the Fierce Biotech Summit on gene editing innovations and battling biotech's bear market. |
|
|---|
|
|
| eBook Improve your congress competitive intelligence and cut down costs by 50% Sponsored by: Ferma.AI, a Product of ZoomRx |
| Executive Summary How a new app brings the power of CRM to a leading lab instruments provider’s field service engineers Sponsored by: Cognizant |
| eBookImprove patient engagement, adherence, and outcomes Sponsored by: Health Catalyst |
| Whitepaper Supporting your product development programme through experience, expertise, and efficiency. Sponsored by: Almac Pharma Services |
| VideoLearn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue. Sponsored by: Proscia |
| VideoCan an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster? Sponsored by: Proscia |
| WhitepaperWhat is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
| ResearchLearn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
| WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
| Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
| WebinarYpsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
| Whitepaper How can we predict the ability of a preclinical drug to inadvertently cause or intentionally inhibit cytokine secretion and T cell activation Sponsored by: ReachBio | The Cell Biology Experts™ |
| Custom Resource Center Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
| Whitepaper Read our whitepaper and dive into the way healthcare providers can digitally transform day-to-day work by streamlining costs and increasing agility by removing manual paper burdens. Sponsored by: DocuSign |
| Research Learn how a private health insurance company uses analytics to deliver exceptional service to its employees and members Sponsored by: Genpact |
| Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
| Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
| Whitepaper This paper explores how Medical Affairs is increasingly playing a key leadership role in evidence planning and generation (part 3 in a series). Sponsored by: Blue Matter, strategic consultants in the life sciences |
| Whitepaper Explore how Thermo Scientific’s Process Liquid Preparation Services can help you plan for scalable buffer preparation. Sponsored by: Thermo Fisher Scientific |
| Research TwinRCTs require fewer patients and shorten trial timelines for rare neurodegenerative diseases. Sponsored by: Unlearn AI |
| eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent |
| Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent |
| Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent |
| Multimedia ZS helps life sciences companies shape the future of medicine by turning healthcare data into transformative insights. Discover the power of R&D innovation Sponsored by: ZS |
| |
|
